SA News • Tue, Dec. 16
There are no Focus articles on CHRS.
There are no Transcripts on CHRS.
Tue, Dec. 16, 6:21 AM
Mon, Dec. 15, 4:17 PM
Thu, Dec. 4, 4:37 PM
Thu, Nov. 6, 1:59 PM
- Biosimilar firm Coherus BioSciences (NASDAQ:CHRS) encounters less-than-expected investor interest in its first day of trading. Shares are off more than 5% from the $13.50 IPO price.
- The late-clinical-stage biotech's lead product is an anti-TNF (tumor necrosis factor) biosimilar to Amgen's (AMGN +0.9%) Enbrel (etanercept) currently in Phase 3 development.
- The company generates no revenue at present. Its net loss was $53.6M in 2013 and $50.1M in 1H 2014.
- ETFs: IBB, BIB, BIS (NYSEARCA:IPO)
We currently have no instablog posts on this stock.
Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.
CHRS vs. ETF Alternatives
Other News & PR